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Introduction: Biomarkers have the potential to improve the clinical management of patients with AAA.
Report: A prospective, proteomics discovery study was undertaken to compare patients with AAA
(n ¼ 20) to matched screened controls (n ¼ 19) for plasma protein expression. Surface-Enhanced-Laser-
Desorption-Ionization Time of Flight Mass Spectrometry (SELDI ToF MS) coupled with Artiﬁcial Neural
Networks (ANN) analysis identiﬁed six protein related diagnostic biomarker ions with a combined AUC
of 0.89.
Discussion: This study discovered a signature plasma protein proﬁle for patients with AAA and
demonstrated that mass spectrometric based research for disease speciﬁc biomarker of AAA is feasible.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Biomarkers may aid the diagnosis of AAA, predict progression
and allow assessment of response to surgical and non-surgical
treatments. Advances in mass spectrometry and statistical data
analysis now allow high throughput screening of plasma for
potentially useful biomarkers using a non-hypothesis based
approach. The aim of this study was to use mass spectrometry to
discover protein signatures that could discriminate AAA patients
from healthy controls.Report
Ethical approval for the study was granted by the Leicestershire,
Northamptonshire and Rutland Research Ethics Committee (REC
Study Reference # 6819). Written informed consent was obtained
from all participants.
Twenty patients (median age 78.5 years, range 66e87) with
AAA (median diameter 5.6 cm, range 3.8e8.2) and 19 ultrasound
screened controls (median age 75 years, range 65e86) with normaly Group, Level 2, Robert Kil-
rmary, Leicester LE2 7LX, UK.
ciety for Vascular Surgery. Publishaortic diameter (<2.5 cm) were prospectively recruited. All study
participants were white European men. The exclusion criteria for
the study were; any acute infective process, inﬂammatory condi-
tion or malignancy. Blood was collected at rest using standardized
blood collection and plasma separation protocols (see supple-
mental material S2 for detailedmethods). Therewas no freeze thaw
cycle prior to ﬁnal analysis. The weak cation exchange chromato-
graphic surface (Protein Chip CM 10 array from Bio-Rad Labora-
tories Inc, California) was used for plasma preparation for SELDI ToF
analysis. The arrays were prepared according to the manufacturer’s
standard protocol with HEPES buffer using automated liquid
handling (BiomekeFX from Beckman Coulter Inc, California).
SELDI-Tof MS (PCS 4000 instrument, Ciphergen Inc. California) was
used to generate spectral data in a single 6 h time period. Mass
spectra were successfully obtained from all samples. The spectral
data were analysed using a stepwise ANN analysis. A total of 11425
plasma protein ions were screened for associationwith AAA. At this
stage principal component analysis was undertaken as a quality
control measure which identiﬁed two outliers with aberrant
spectra. These spectra were excluded from further analysis (1 AAA
and 1 control). Further details of the process of ANN analysis are
given in the supplementary material (S1). These analyses identiﬁed
protein ions from the spectral data which could differentiate
plasma samples from patients with AAA in a mixed population. The
mass/charge ratio (m/z in Daltons) values for these ions were 992.3,
10710.7, 11249.6, 14465.1, 15201.7, and 13390.5 Da. The sensitivityed by Elsevier Ltd. All rights reserved.
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were calculated at 85.0% and 81.4% respectively. A classiﬁer con-
sisting of these six ions showing (individually) a difference in
expression between AAA and controls was identiﬁed. The area
under the curve (AUC) for these potential biomarker classiﬁers
(treated as single entities) was calculated as 0.89 by receiver
operating characteristics (ROC) analysis (Fig. 1b). Internal cross-
validation of the biomarker panel was undertaken on blinded
data from the same study population. Testing this classiﬁer onFigure 1. (a) Sample SELDI-Tof Mass Spectra of AAA and control. Signal intensity is
(UA ¼ microamperes). (b) Receiver operating characteristic analysis for the six ion biomark
blinded data to discriminate cases (red bars) from controls (blue bars) At a cut-off of 50% pr
black error bars represent the associated standard error.blinded samples (same study population) as a diagnostic test
demonstrated that the majority of samples were correctly assigned
(Fig. 1c). At a probability threshold of 0.5 only 5 incorrect assign-
ments were seen (2 AAA, 3 controls).
Discussion
Multiple proteins (serum elastin peptides and plasmine
antiplasmin complexes, Matrix-degrading metalloproteinase 9,shown on the y-axis (note variable scale) and mass to charge ratio on x-axis
er classiﬁer. AUC ¼ 0.89. (c) Cross Validation. The biomarker panel was tested against
obability (horizontal line) there were 5 incorrect assignments (2 AAA, 3 controls). The
S. Ehsan et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 52e5454interferon-gamma, C-reactive protein, alpha 1-antitrypsin and
lipoprotein (a), thrombin activation measured as APC-PCI and IL-6)
have been investigated as biomarkers or risk factors for AAA.
Although these proteins have been shown to be associated with
AAA none have been independently validated or have found the
potential for clinical use. Therefore further discovery studies to
investigate other methodologies and new candidates are a valid
avenue for further research.1e3 This study has shown that a modern
but relatively simple, automated high throughput proteomics
technique can be used to study the plasma protein expression of
AAA. This signature plasma protein proﬁle can identify patients
from a mixed population group.
In conclusion, this study has discovered a unique plasma protein
expression for patients with AAA. The biomarker of AAA (classiﬁer
comprising of six ions) was found to be highly discriminatory for
the disease. This differential expressionmerits further investigation
as a risk stratiﬁcation tool. In addition advanced proteomic tech-
niques can be used for in depth analysis to discover proteins that
are responsible for this differential expression and the pathological
pathways that are dysregulated in patients with AAA.Conﬂict of Interest/Funding
None.Appendix A. Supplementary data
Supplementary data related to this article can be found online at
doi:10.1016/j.ejvs.2012.04.018.References
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